LEVITRA® 20mg Special Drug Use Investigation (Long-term)

Bayer1,221 enrolled

Overview

This investigation targets either the patients of 18 years-old or older and under 65 years-old with organic or mixed erectile dysfunction (ED) who cannot obtain sufficient efficacy by dose 10mg of Levitra, and the target patients dose is increased to Levitra 20mg. This investigation will be limited to the patients whose tolerability of Levitra 10mg is judged to be no problem.

Study Type

OBSERVATIONAL

Enrollment

1,221

Conditions

Erectile Dysfunction

Interventions

Vardenafil, (Levitra, BAY38-9456)DRUG

Patients under daily life treatment receiving Levitra according to local drug information.

Eligibility

Sex: MALEMin age: 18 YearsMax age: 64 Years

Medical Language ↔ Plain English

Inclusion Criteria: * This investigation targets either the patients of 18 years-old or older and under 65 years-old with organic or mixed erectile dysfunction who cannot obtain sufficient efficacy by dose 10mg of Levitra, and the target patients dose is increased to Levitra 20mg. This investigation will be limited to the patients whose tolerability of Levitra 10mg is judged to be no problem.

Locations (1)

Unnamed facility

Many Locations, Japan

Outcomes

Primary Outcomes

Efficacy of patients with LEVITRA treatment

Time frame: After 6 months

Secondary Outcomes

LEVITRA treatment improved the patient's erection

Time frame: After 6 months

LEVITRA improved the patient's erection after Minimum and Maximum Intervals between LEVITRA intake and the start of intercourse

Time frame: After 6 months

Reporting a second successful intercourse within 24 hours of dosing

Time frame: After 6 months

Patients prefer LEVITRA over last Erectile Dysfunction treatment

Time frame: After 6 months

Tolerability of patients with LEVITRA treatment

Time frame: After 6 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.